![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
NEPTUNE STUDY: ON-TREATMENT HBsAg LEVEL ANALYSIS CONFIRMS PREDICTION OF RESPONSE OBSERVED IN PHASE 3 STUDY OF PEGINTERFERON ALFA-2A IN HBeAg-POSITIVE PATIENTS
|
|
|
Reported by Jules Levin EASL 2011 Berlin Germany March 30-Apr 2
E Gane, J Jia, K Han, T Tanwandee, WL Chuang, P Marcellin,
HLY Chan, T Piratvisuth, C Wat, E Martins, Y-F Liaw
Liver Unit, Auckland City Hospital, Auckland, New Zealand
Study objective:
To determine whether early on-treatment HBsAg monitoring could be used to identify post-treatment responders or non responders to PEG-IFNα-2a (180 μg/48 weeks)
![EASL1.gif](../images/041311/041311-4/EASL1.gif)
![EASL2.gif](../images/041311/041311-4/EASL2.gif)
![EASL3.gif](../images/041311/041311-4/EASL3.gif)
![EASL4.gif](../images/041311/041311-4/EASL4.gif)
![EASL5.gif](../images/041311/041311-4/EASL5.gif)
![EASL6.gif](../images/041311/041311-4/EASL6.gif)
![EASL7.gif](../images/041311/041311-4/EASL7.gif)
![EASL8.gif](../images/041311/041311-4/EASL8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|